CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
about
Thrombotic microangiopathy with targeted cancer agentsBeyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologicsAntineoplastic agents and thrombotic microangiopathy.Immunogenicity of mAbs in non-human primates during nonclinical safety assessmentIntensive immunosuppression treatment for central retinal vein occlusion in a young adult: a case report.Alemtuzumab therapy for multiple sclerosis.Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionFrom bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies.Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.Biologic therapies: what and when?Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseA review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.T cell-directed therapies: lessons learned and future prospects.Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.The role of biologics in treatment of ANCA-associated vasculitis.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Emerging cell and cytokine targets in rheumatoid arthritis.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Atacicept as an investigated therapy for rheumatoid arthritis.The immunological function of CD52 and its targeting in organ transplantation.Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.Alemtuzumab induction therapy in solid organ transplantation.Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.Immunogenicity screening in protein drug development.Alemtuzumab and chronic plaque psoriasis.[Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy].Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860
Q24635904-656BC570-163B-4639-97B4-5A686CBD3B71Q26826924-BC7A873A-0D5E-49CB-AE7D-C9FFB6B51C2AQ30251919-3DED627E-8F85-4B99-8880-532DAA8086D6Q30390955-9B432EC7-700F-4D00-B60D-460D832F465FQ31144038-D50373D9-8555-4D13-9360-9C49AB225E4BQ33404568-F4BCD4BE-348A-4BA9-A482-7EA0B90E70D3Q33760317-5D7A8991-1FE3-4BA5-9AB3-D35FF8C02CAAQ34175958-F1C77016-B141-42FA-979A-2F96A9794A2EQ34321820-F97AD542-7EA4-44BF-BBCD-0E612A384E0BQ34395747-7B217361-5758-409E-9A0F-8E2DE1969272Q34488656-A81ED2C5-E6DB-4EAA-AD94-89DC0C26BDA5Q35770607-F823B530-740C-4D96-A7CF-321AF126F9F7Q36024673-1604D95D-CCAC-438E-BCAC-FDDCB56E3218Q36194538-74CCF7B3-398A-45AB-BA6C-6AA0BBEFE56EQ36453638-9DFB7B22-9E69-466D-A1CA-B63365D1F98FQ36688370-B2C4DAC4-5DBA-48EB-A6AF-2CE88E3DF937Q37781913-AC2168D3-A215-4498-ABF9-F1CBCE0BC444Q37950904-0A0585B2-B3B9-4442-B611-D55C95D095AFQ38071110-4127796E-633B-41F8-B13F-A51DD2A05DC5Q38161794-49AB80EA-322C-46EC-8C06-4217F6FEE059Q38203622-8DA9043E-C72C-40A6-AEC4-3F6CF0E1CD32Q38235570-18F914F9-CD18-487E-9214-3F454CA17C58Q38747419-E4D4FC1A-FC72-499D-BA0E-CE0187036EFEQ39452477-B1D773D0-8FA6-4F5F-B472-24C6747B5AC0Q42876591-0757AA49-E7AE-4248-90AE-083ED9D4CF36Q46817686-AD6A42A8-6A21-4B72-8192-8CE8DA53E584Q49168236-175790A8-24D1-4133-B93A-E64D1EBE2CF0Q50852822-C03CAA59-BB3B-43E5-A99F-9BC92EFB531BQ52885796-17635DF4-2F68-4EA8-9984-4B44399391B5Q59129976-D723A597-2876-4CAB-851F-D406CF987E62
P2860
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
@en
type
label
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
@en
prefLabel
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
@en
P2093
P356
P1476
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
@en
P2093
B L Hazleman
E L Matteson
E W St Clair
J D Isaacs
J M Johnston
K J Bulpitt
T J Schnitzer
P304
P356
10.1093/RHEUMATOLOGY/35.3.231
P577
1996-03-01T00:00:00Z